ULTRAGENYX PHARMACEUTI

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

21 дек 2023 13:30:00 Источник Nasdaq GlobeNewswire

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

18 дек 2023 05:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx to Participate at Investor Conferences in November

20 ноя 2023 13:30:00 Источник Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

17 ноя 2023 13:30:00 Источник Nasdaq GlobeNewswire

Ultragenyx to Participate in the Jefferies London Healthcare Conference

07 ноя 2023 14:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update

02 ноя 2023 13:05:01 Источник Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update

26 окт 2023 13:05:00 Источник Nasdaq GlobeNewswire

Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

23 окт 2023 13:01:00 Источник Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 окт 2023 13:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

18 окт 2023 18:16:45 Источник Nasdaq GlobeNewswire

Ultragenyx Announces Proposed Public Offering of Common Stock

17 окт 2023 13:02:14 Источник Nasdaq GlobeNewswire

Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease

16 окт 2023 05:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

14 окт 2023 13:30:00 Источник Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

12 окт 2023 14:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)

09 окт 2023 05:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023

05 окт 2023 05:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 сен 2023 14:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx to Participate at Investor Conferences in September

31 авг 2023 06:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18 авг 2023 14:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update

03 авг 2023 13:00:00 Источник Nasdaq GlobeNewswire